Fang Bai Ph.D.

Scientific Director


   Fang Bai Ph.D. 

Scientific Director of Biomedical Big Data Platform

Assistant Professor      

Principal Investigator


Shanghai Institute for Advanced Immunochemical Studies

School of Life Science and Technology

Research Area 

                          Drug Design and Development   
Contact Info.   



2004-2009: Dalian University of Technology, BE in Chemical Engineering and BA in English;

2009-2014: Dalian University of Technology(Jointly educated by Shanghai Institute of Materia Medica, Chinese Academy of Sciences)


2014.8-2019.5 Postdoctoral Research Fellow, Rice University;

2019.5-2019.9 Assistant Professor of Research, University of Texas Health Science Center at Houston;

2019.10-present Assistant Professor, ShanghaiTech University


Research Interests

1.  Developing computational drug discovery and design methodologies by combining artificial intelligence algorithms and theories of computational drug design methods, especially focusing on fragment-based drug design, PROTACs design and large-scale conformational sampling of proteins.

2.  Cancer drug discovery and design, mainly targeting against tumor metastasis and immune escape.


Selected Publications

  1. A. Amir1, F. Bai1,Y. Sohn, L. Song, S. Tamir, H. Marjault, G. Mayer, O. Karmi, P. Jennings, R. Mittlerf, J.N. Onuchic, A. Friedler, and R. Nechushtai. The anti-apoptotic proteins NAF-1 and iASPP interact to drive apoptosis in cancer cells. Chem. Sci. 2019, 10: 665-673(1Co-first Author).

  2. F. Bai, X. Pi, P. L, P. Zhou, H. Yang, X. Wang, M. Li, Z. Gao, H. Jiang. A Statistical Thermodynamic Model for Ligands Interacting With Ion Channels: Theoretical Model and Experimental Validation of the KCNQ2 Channel. Front. Pharmacol. 2018, 9:150.

  3. F. Bai, K. Liu, H. Li, J. Wang, J. Zhu, P. Hao, L. Zhu, S. Zhang, L. Shan, W. Ma, W. Zhang, H. Li, A.M. Bode &Z. Dong. Veratraimine modulates AP-1-depdendent gene transcription by directly binding to programmable DNA. Nucleic Acids Res. 2017, 46:546-557.

  4. F. Bai, F. Morcos, RR. Cheng, H. Jiang and J.N. Onuchic. Elucidating the druggable interface of protein-protein interactions using fragment-docking and coevolutionary analysis. Proc. Natl. Acad. Sci. USA. 2016, 113: E8051–E8058.

  5. F. Bai, F. Morcos, Y.S. Sohn, Darash-Yahana M., C.O. Rezende, C.H. Lipper, M.L. Paddock, L. Song, Y. Luo, S.H. Holt, S. Tamir, E.A. Theodorakis, P.A. Jennings, J.N. Onuchic, R. Mittler, and R. Nechushtai. The Fe-S cluster-containing NEET proteins mitoNEET and NAF-1 as chemotherapeutic targets in breast cancer. Proc. Natl. Acad. Sci. USA. 2015, 12: 3698-3703.

  6. F.Bai, S. Liao, J. Gu, H. Jiang, X. Wang, H. Li. An accurate metalloprotein-specific scoring function and molecular docking program devised by a dynamic sampling and iteration optimization strategy. J. Chem. Inf. Model. 2015, 55: 833-847.

  7. F.Bai, Y.Xu, J.Chen, Q.Liu, J.Gu, X.Wang, J.Ma, H. Li, J.N. Onuchic, and H.Jiang.  Free energy landscape for the binding process of Huperzine A to acetylcholinesterase.Proc. Natl. Acad. Sci. USA. 2013, 110:4273-4278.

  8. F.Bai, H. Liu, L. Ton, W. Zhou, L. Liu, Z. Zhao, X. Liu, H. Jiang, X. Wang, H. Xie, and H. Li Discovery of novel selective inhibitors for EGFR-T790M/L858R. Bioorg. Med. Chem. Lett. 2012, 22:1365-1370.

  9. F.Bai, X. Liu, J. Li, H. Zhang, H. Jiang, X. Wang, and H. Li. Bioactive Conformational Generation of Small Molecules: A Comparative Analysis between Force-Field and Multiple Empirical Criteria Based Methods.BMC Bioinformatics 2010, 11:545.

  10. C. Lipper, J. Stofleth, F. Bai, Y. Sohn, S. Roy, R. Mittler, R. Nechushtai, J.N. Onuchic, P. Jennings. Redox-dependent gating of VDAC by mitoNEET. Proc. Natl. Acad. Sci. USA. 2019, 116: 19924-19929.

  11. Z. Tan, L. Xiao, M. Tang, F. Bai, J. Li, L. Li, F. Shi, N. Li, Y. Li, Q. Du, J. Lu, X. Weng, W. Yi, H. Zhang, J. Zhou, Q. Gao, J.N. Onuchic, A.M. Bode, X. Luo, Y. Cao. Targeting CPT1A-mediated fatty acid oxidation sensitizes nasopharyn